Skip to content Skip to footer
Subscribe Now
TOP 20

Top 20 Diagnostics Companies of 2025 

Top 20 Diagnostics Companies of 2025  Shots:  Driven by continuous innovation and enhanced precision, the diagnostic industry is advancing rapidly, transforming the way healthcare is delivered  In 2025, the global diagnostic testing market is valued at approximately $207.96B in 2025 and is projected to grow to around $272.9B by 2034, reflecting a CAGR of 3%.…
May 29, 2025

Read more

Atherosclerosis
INSIGHTS+

Disease of the Month – Atherosclerosis 

Shots:  Characterized by the thickening or hardening of arteries due to plaque buildup, atherosclerosis leads to complications like heart attack or stroke  PharmaShots' Disease of the Month report aims to familiarize the general population with conditions impacting communities worldwide. The report outlines disease characteristics, types, symptoms, diagnosis, treatments, epidemiology, market size, clinical trial analysis, patient…
May 28, 2025

Read more

INSIGHTS+

New Drug Designations – April 2025  

Shots:     PharmaShots’ Designation Report provides a concise overview of the latest drug designations granted by major regulatory authorities, including the FDA, EMA, MHLW, Health Canada and NMPA   The April 2025 report covers designations granted to 36 drugs and 6 medical devices, spanning 14 small molecules, 3 biologics, 11 cell and gene therapies & 6 medical devices among…
May 27, 2025

Read more

Chronic Dermatologic Care: Baldo Scassellati Sforzolini from Galderma in Conversation with PharmaShots
VIEWPOINTS

Chronic Dermatologic Care: Baldo Scassellati Sforzolini from Galderma in Conversation with PharmaShots

Shots:  Recently, the groundbreaking results from Galderma’s Phase III OLYMPIA 1 trial were published in JAMA Dermatology. The study evaluated nemolizumab in patients with moderate-to-severe active prurigo nodularis  The trial met all primary and secondary endpoints, with results aligning with those from the OLYMPIA 2 trial, reinforcing nemolizumab’s potential in achieving sustained improvements in the…
May 26, 2025

Read more

Top 20 Medical device companies of 2025
TOP 20

Top 20 Medical Device Companies of 2025

Shots:  Driven by continuous innovation, the MedTech sector is evolving rapidly to enhance preventive, diagnostic, and therapeutic capabilities in healthcare In 2023, the global MedTech market was valued at $668.2B and is projected to reach $989.1B by 2033, growing at a CAGR of approximately 4%. Medtronic led the industry with a revenue of $33.12B, followed…
May 22, 2025

Read more

Infusing Automation: Suresh Kannan from Model N in an Illuminating Discussion with PharmaShots
VIEWPOINTS

Infusing Automation: Suresh Kannan from Model N in an Illuminating Discussion with PharmaShots

Shots:  Identifying discrepancies remains a key challenge for manufacturers in mitigating revenue leakage and ensuring alignment with payer plans  Suresh Kannan, Model N’s Chief Product Officer, offers insights into the newly launched GenAI and enhanced data solutions aimed at optimizing revenue and ensuring compliance  He also outlines a strategic approach to formulary identification and emphasizes…
May 21, 2025

Read more

Advancing Lupus Research: Devon Kelly from Lupus Nexus in a Stimulating Conversation with PharmaShots
VIEWPOINTS

Advancing Lupus Research: Devon Kelly from Lupus Nexus in a Stimulating Conversation with PharmaShots

Shots:  Research into Lupus has yielded groundbreaking results in pharmacokinetics and pharmacodynamics, yet experts still don't understand its cause  Lupus Research Alliance (LRA) recently launched a platform called Data Repository, Exchange, and Analytics (DREAM) for data sharing and partnerships for research in lupus  Devon Kelly, Director of Lupus Nexus at the Lupus Research Alliance, sheds…
May 19, 2025

Read more

Know Your Investor: Alexandria Venture (May’25 Edition)
INSIGHTS+

Know Your Investor: Alexandria Venture (May’25 Edition)

Shots:     Welcome to the 2025 edition of Know Your Investor, spotlighting leading venture capital firms driving innovation in healthcare.  This edition features Alexandria Venture Investments, a firm committed to supporting disruptive life science companies that aim to improve human health.  In 2024, the firm invested approximately $2.7B across six public and private funding rounds, adding…
May 15, 2025

Read more

Load more